Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast (G7)

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all competing largely for a share of the TNF-refractory population. The continued launch of biosimilars in the major pharmaceutical markets will only add to the competition. Increasing safety concerns surrounding the JAK inhibitor class have delayed their use until after anti-TNF drugs in the United States, reducing their overall uptake. Although the late-phase pipeline for RA is sparse, the sheer number of biologics and targeted oral therapies available to treat the disease ensures that marketers will face fierce competition and increasing challenges to gain and maintain market share.

Questions answered

• What are physicians’ preferred TNF-alpha inhibitors for RA, and what factors drive these preferences? Given the increasingly fragmented market, how likely are physicians to cycle through anti-TNF agents before progressing to a novel mechanism of action?
• How has / will the entry and continued uptake of biosimilars affect sales and patient shares of currently marketed RA agents and emerging therapies?
• What are physicians’ perceptions of currently marketed non-TNF biologics and oral JAK inhibitors for RA? Where are these agents positioned in the treatment algorithm, and which agents have been most successful in targeting the TNF-refractory population?
• What are the drivers and constraints in the RA therapy market, and how will the market evolve over the forecast period?

Content highlights

Markets covered: United States, EU5, Japan

Primary research: 29 country-specific interviews with thought-leading rheumatologists

Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity

Forecast: 10-year, annualized, drug-level sales and patient share of key RA therapies through 2034, segmented by brands / generics / biosimilars

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.